Vertex/Glaxo Wellcome Agenerase
Executive Summary
Fast-track NDA submission for HIV protease inhibitor amprenavir (141W94, VX-478) is completed Oct. 16. The clinical package contains 20 trials in 1,500 patients. Amprenavir is dosed 1,200 mg (eight 150 mg capsules) twice-daily, as opposed to most protease inhibitors, which require dosing three times per day. Two-, three-, and four-drug combination regimens were tested, with various nucleoside and non-nucleoside reverse transcriptase inhibitors. Glaxo's Epivir and Retrovir, as well as the pending Ziagen were among the nucleoside analogs. The NDA submission is the first for Cambridge, Mass.-based Vertex, which will co-promote the product with Glaxo
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth